PRINCETON, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Medarex, Inc. today announced that effective October 22, 2007, Ursula B. Bartels is appointed Senior Vice President of the company. Following a brief transition period, Ms. Bartels will assume full responsibilities of General Counsel and Secretary of Medarex from W. Bradford Middlekauff. Mr. Middlekauff will become Senior Vice President, Strategic Planning of Medarex. Ms. Bartels will oversee Medarex’s legal department and be responsible for the company’s global legal strategy.
Ms. Bartels brings to Medarex more than 20 years of industry experience. She was most recently Vice President, General Counsel and Secretary of Chiron Corporation until April 2006, when it was acquired by Novartis. Prior to joining Chiron, Ms. Bartels served as Senior Vice President, General Counsel and Secretary of Boehringer Ingelheim Corporation, where she was responsible for all legal, and compliance functions for the US businesses. Before that, she spent 11 years at SmithKline Beecham Corporation, serving in various capacities in the legal department, culminating in the position of Vice President and Associate General Counsel, Legal Operations North America. Ms. Bartels received her J.D. from the University of Virginia, and did her undergraduate work at Bryn Mawr College.
“Ursula brings enormous experience to Medarex,” said Howard H. Pien, President and CEO of Medarex. “With her deep knowledge of the pharmaceutical industry and broad range of experiences in corporate governance, regulatory compliance, and global intellectual property strategy, I have complete confidence that Ursula will be an invaluable addition to the Medarex management team as we continue to grow and strengthen our position in the field of antibody therapeutics.”
Mr. Pien also said, “I’d like to thank Brad Middlekauff for his contribution to Medarex over the last seven years, during which he has played a key role.”
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, ext. 2216, or
Jean Mantuano, Corporate Communications (media), +1-609-430-2880, ext.
2221, both of Medarex, Inc.
Web site: http://www.medarex.com/
Company News On-Call: http://www.prnewswire.com/comp/108265.html /
